Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.7029
0.045.84%
At close: -
$0.7029
0.000.00%
After Hours: 4:17 PM EDT
Comments
Loading...
Context Therapeutics Analyst Ratings and Price Targets | NASDAQ:CNTX | Benzinga
Context Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Context Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
HC Wainwright & Co.
JMP Securities
Piper Sandler
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Context Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert48% | $9 → $9 | Maintains | Buy | Get Alert |
| 04/29/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert48% | $9 → $9 | Maintains | Buy | Get Alert |
| 04/21/2025 | Buy Now | — | William Blair | Matt Phipps25% | — | Initiates | → Outperform | Get Alert |
| 04/09/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert48% | $9 → $9 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert48% | $9 → $9 | Maintains | Buy | Get Alert |
| 01/15/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert48% | $9 → $9 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | — | JMP Securities | Silvan Tuerkcan47% | → $4 | Initiates | → Market Outperform | Get Alert |
| 11/25/2024 | Buy Now | — | D. Boral Capital | Jason Kolbert48% | → $9 | Initiates | → Buy | Get Alert |
| 09/23/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar37% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar37% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | — | Piper Sandler | Joseph Catanzaro46% | → $4.5 | Initiates | → Overweight | Get Alert |
| 05/09/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar37% | $4 → $5 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | — | Maxim Group | Jason McCarthy42% | $4 → $10 | Maintains | Buy | Get Alert |
| 03/21/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar37% | $5 → $4 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar37% | → $5 | Upgrade | Neutral → Buy | Get Alert |
| 09/11/2023 | Buy Now | — | Maxim Group | Jason McCarthy42% | → $4 | Initiates | → Buy | Get Alert |
| 06/06/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar37% | — | Reiterates | → Neutral | Get Alert |
| 03/23/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar37% | — | Downgrade | Buy → Neutral | Get Alert |
| 02/07/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar37% | → $4 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Context Therapeutics (CNTX) stock?
The latest price target for Context Therapeutics (NASDAQ:CNTX) was reported by D. Boral Capital on May 8, 2025. The analyst firm set a price target for $9.00 expecting CNTX to rise to within 12 months (a possible 1180.41% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Context Therapeutics (CNTX)?
The latest analyst rating for Context Therapeutics (NASDAQ:CNTX) was provided by D. Boral Capital, and Context Therapeutics maintained their buy rating.
When was the last upgrade for Context Therapeutics (CNTX)?
The last upgrade for Context Therapeutics Inc happened on November 1, 2023 when HC Wainwright & Co. raised their price target to $5. HC Wainwright & Co. previously had a neutral for Context Therapeutics Inc.
When was the last downgrade for Context Therapeutics (CNTX)?
The last downgrade for Context Therapeutics Inc happened on March 23, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Context Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Context Therapeutics (CNTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Context Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Context Therapeutics was filed on May 8, 2025 so you should expect the next rating to be made available sometime around May 8, 2026.
Is the Analyst Rating Context Therapeutics (CNTX) correct?
While ratings are subjective and will change, the latest Context Therapeutics (CNTX) rating was a maintained with a price target of $9.00 to $9.00. The current price Context Therapeutics (CNTX) is trading at is $0.70, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
